3300 Bee Cave Road
Suite 650-227
Austin, TX 78746
United States
877 774 4679
https://www.genprex.com
Settore/i:
Settore:
Impiegati a tempo pieno: 26
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. John Rodney Varner | Co-Founder, Chairman, President & CEO | 886,97k | N/D | 1957 |
Mr. Ryan M. Confer M.S. | Chief Financial Officer | 606,57k | N/D | 1982 |
Mr. David M. Schloss | Senior Vice President of Human Resources | N/D | N/D | N/D |
Mr. Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property & Licensing | N/D | N/D | N/D |
Dr. Mark S. Berger M.D. | Chief Medical Officer | N/D | N/D | 1955 |
Dr. Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs & Quality | N/D | N/D | N/D |
Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific & Medical Advisory Board | N/D | N/D | N/D |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
L'ISS Governance QualityScore di Genprex, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.